Trial Profile
A Multinational Phase IV Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms TAURUS
- Sponsors Bayer
- 19 Dec 2022 Final results of the 2-year , assessing weekly prophylaxis dosing regimens of octocog alfa, published in the European Journal of Haematology
- 25 Mar 2021 Status changed from active, no longer recruiting to completed.
- 27 Jan 2021 Planned End Date changed from 30 Jun 2022 to 1 Mar 2021.